Evaluation of a therapeutic vaccine for the prevention of recurrent urinary tract infections versus prophylactic treatment with antibiotics

International Urogynecology Journal and Pelvic Floor Dysfunction

Volumn 24, Issue 1, 2013, Pages 127-134

  Lorenzo Gomez M F ^a   Padilla Fernandez B ^a   Garcia Criado F J ^b   Miron Canelo J A ^b   Gil Vicente, A ^a   Nieto Huertos, A ^b   Silva Abuin, J M ^a  

^a INSTITUTO DE INVESTIGACIÓN BIOMÉDICA DE SALAMANCA IBSAL   (Spain)

^b UNIVERSITY OF SALAMANCA   (Spain)

Author keywords

Bacterial vaccine; Recurrent urinary tract infections

Indexed keywords

BACTERIAL VACCINE; COTRIMOXAZOLE; UNCLASSIFIED DRUG; UROMUNE;

ADOLESCENT; ADULT; AGED; ANTIBIOTIC PROPHYLAXIS; APPLICATION SITE REACTION; ARTICLE; BACTERIAL CELL; BACTERIAL STRAIN; BACTERIUM CULTURE; BACTERIUM ISOLATION; CITROBACTER KOSERI; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; CONTROLLED STUDY; COST OF ILLNESS; DISEASE DURATION; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; ENTEROBACTER AEROGENES; ENTEROBACTER CLOACAE; ENTEROCOCCUS FAECALIS; ESCHERICHIA COLI; FEMALE; GRAM NEGATIVE INFECTION; GRAM POSITIVE INFECTION; HUMAN; INFECTION PREVENTION; KLEBSIELLA OXYTOCA; KLEBSIELLA PNEUMONIAE; MAJOR CLINICAL STUDY; MULTICENTER STUDY (TOPIC); NONHUMAN; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROTEUS MIRABILIS; PROTEUS VULGARIS; PSEUDOMONAS AERUGINOSA; RECURRENT INFECTION; STAPHYLOCOCCUS EPIDERMIDIS; STAPHYLOCOCCUS SAPROPHYTICUS; SYSTEMIC DISEASE; TREATMENT DURATION; URINARY TRACT INFECTION;

ANALYSIS OF VARIANCE; ANTIBIOTIC PROPHYLAXIS; BACTERIAL VACCINES; FEMALE; HUMANS; MIDDLE AGED; RECURRENCE; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME; URINARY TRACT INFECTIONS;

EID: 84872282337     PISSN: 09373462     EISSN: 14333023     Source Type: Journal    
DOI: 10.1007/s00192-012-1853-5     Document Type: Article

References (36)

1. Foxman B (2002) Epidemiology of urinary tract infections: incidence, morbidity, and economic costs. Am J Med 113(Suppl 1A):5S-13S
2. Nicolle LE (2005) Managing recurrent urinary tract infections in women. Womens Health (Lond Engl) 1(1):39-50
3. Naber KG, Cho YH, Matsumoto T, Schaeffer AJ (2009) Immunoactive prophylaxis of recurrent urinary tract infections: a meta-analysis. Int J Antimicrob Agents 33(2):111-119
4. Cox CE, Lacy SS, Hinman F Jr (1968) The urethra and its relationship to urinary tract infection. II. The urethral flora of the female with recurrent urinary infection. J Urol 99(5):632-638
5. Rahn DD (2008) Urinary tract infections: contemporary management. Urol Nurs 28(5):333-341, quiz 342
6. Grabe M, Bjerklund-Johansen T, Botto H, Çek M, Naber K, Tenke P et al (2010) Guidelines on urological infections. Urology. EAU Guidelines Office, Arnhem
7. Mulholland SG (1986) Controversies in management of urinary tract infection. Urology 27(2 Suppl):3-8
8. U.S. Census Bureau. U.S. interim projections by age, sex, race, and Hispanic origin (2008) http://wwwcensusgov/population/www/projections/ usinterimproj/
9. Mayer TR (1980) UTI in the elderly: how to select treatment. Geriatrics 35(3):67-77
10. Turck M, Stamm W (1981) Nosocomial infection of the urinary tract. Am J Med 70(3):651-654
11. Nicolle LE, Ronald AR (1987) Recurrent urinary tract infection in adult women: diagnosis and treatment. Infect Dis Clin North Am 1(4):793-806
12. Palou J, Pigrau C, Molina I, Ledesma JM, Angulo J, Grupo Colaborador Español del Estudio ARESC (2011) [Etiology and sensitivity of uropathogens identified in uncomplicated lower urinary tract infections in women (ARESC Study): implications on empiric therapy.]. Med Clin (Barc) 136(1):1-7
13. Carné X, Moreno V, Porta Serra M, Velilla E (1989) Calculating the number of patients necessary for designing a clinical study (in Spanish). Med Clin (Barc) 92(2):72-77
14. Andreu A, Planells I, Grupo Cooperativo Español para el Estudio de la Sensibilidad Antimicrobiana de los Patógenos Urinario (2008) Etiology of community-acquired lower urinary infections and antimicrobial resistance of Escherichia coli: a national surveillance study (in Spanish). Med Clin (Barc) 130(13):481-486
15. Pigrau-Serrallach C (2005) Recurrent urinary tract infections (in Spanish). Enferm Infecc Microbiol Clin 23(Suppl 4):28-39
16. McEwen LN, Farjo R, Foxman B (2003) Antibiotic prescribing for cystitis: how well does it match published guidelines? Ann Epidemiol 13(6):479-483
17. Glanz SA, Slinker BK (1990) The first step: understanding simple linear regression. In: Glanz SA, Slinker BK (eds) Primer of applied regression and analysis of variance. McGraw-Hill, New York, pp 27-35
18. Lettgen B (1996) Prevention of recurrent urinary tract infections in female children: OM-89 immunotherapy compared with nitrofurantoin prophylaxis in a randomized pilot study. Curr Ther Res Clin Exp 57(6):464-475
19. Bauer HW, Rahlfs VW, Lauener PA, Blessmann GS (2002) Prevention of recurrent urinary tract infections with immuno-active E. coli fractions: a meta-analysis of five placebo-controlled double-blind studies. Int J Antimicrob Agents 19(6):451-456
20. Bauer HW, Alloussi S, Egger G, Blümlein HM, Cozma G, Schulman CC, Multicenter UTI Study Group (2005) A long-term, multicenter, double-blind study of an Escherichia coli extract (OM-89) in female patients with recurrent urinary tract infections. Eur Urol 47(4):542-548, discussion 548
21. Nau GJ, Schlesinger A, Richmond JF, Young RA (2003) Cumulative Toll-like receptor activation in human macrophages treated with whole bacteria. J Immunol 170(10):5203-5209
22. Sato S, Nomura F, Kawai T, Takeuchi O, Mühlradt PF, Takeda K et al (2000) Synergy and cross-tolerance between toll-like receptor (TLR) 2- and TLR4-mediated signaling pathways. J Immunol 165(12):7096-7101
23. Underhill DM, Ozinsky A (2002) Toll-like receptors: key mediators of microbe detection. Curr Opin Immunol 14(1):103-110
24. Holmgren J, Czerkinsky C (2005) Mucosal immunity and vaccines. Nat Med 11(4 Suppl):S45-S53
25. Eriksson K, Quiding-Järbrink M, Osek J, Möller A, Björk S, Holmgren J et al (1998) Specific-antibody-secreting cells in the rectums and genital tracts of nonhuman primates following vaccination. Infect Immun 66(12):5889-5896
26. Kozlowski PA, Cu-Uvin S, Neutra MR, Flanigan TP (1997) Comparison of the oral, rectal, and vaginal immunization routes for induction of antibodies in rectal and genital tract secretions of women. Infect Immun 65(4):1387-1394
27. Quiding M, Nordström I, Kilander A, Andersson G, Hanson LA, Holmgren J et al (1991) Intestinal immune responses in humans. Oral cholera vaccination induces strong intestinal antibody responses and interferon-gamma production and evokes local immunological memory. J Clin Invest 88(1):143-148
28. Cuburu N, Kweon MN, Song JH, Hervouet C, Luci C, Sun JB et al (2007) Sublingual immunization induces broad-based systemic and mucosal immune responses in mice. Vaccine 25(51):8598-8610
29. Negri DR, Riccomi A, Pinto D, Vendetti S, Rossi A, Cicconi R et al (2010) Persistence of mucosal and systemic immune responses following sublingual immunization. Vaccine 28(25):4175-4180
30. Alecsandru D, Valor L, Sánchez-Ramón S, Gil J, Carbone J, Navarro J et al (2011) Sublingual therapeutic immunization with a polyvalent bacterial preparation in patients with recurrent respiratory infections: immunomodulatory effect on antigen-specific memory CD4+ T cells and impact on clinical outcome. Clin Exp Immunol 164(1):100-107
31. Johnson JR, Stamm WE (1989) Urinary tract infections in women: diagnosis and treatment. Ann Intern Med 111(11):906-917
32. World Health Organization. WHO global strategy for containment of antimicrobial resistance (2001) http://wwwwhoint/csr/en/
33. European Medicines Agency. CVMP strategy on antimicrobials 2011-2015 (2011) EMA/CVMP/287420/2010
34. Food and Drug Administration. Combating antibiotic resistance (2011) http://wwwfdagov/ForConsumers/ConsumerUpdates/ucm092810htm
35. Centers for Disease Control and Prevention. Transatlantic Taskforce on Antimicrobial Resistance recommendations: recommendations for future collaboration between the U.S. and EU (2011) http://wwwcdcgov/drugresistance/ pdf/tatfar-reportpdf
36. World Medical Association Declaration of Helsinki. 52nd WMA General Assembly, Edinburgh, Scotland, October 2000. Note of clarification on paragraph 29 added by the WMA General Assembly, Washington 2002. Ethical principles for medical research involving human subjects http://wwwwmanet/e/policy/pdf/17cpdf